# The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

> **NCT06611904** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Attikon Hospital** · enrollment: 60 (actual)

## Conditions studied

- Urine Albumin (UAlb)
- Glycocalyx
- Arterial Stiffness

## Interventions

- **DRUG:** Dulaglutide
- **DRUG:** DPP-4 Inhibitors

## Key facts

- **NCT ID:** NCT06611904
- **Lead sponsor:** Attikon Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-01
- **Primary completion:** 2022-02-05
- **Final completion:** 2024-12-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06611904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06611904, "The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06611904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*